| Dr Relindis Neh-awah Azenwi Fru, MD | |
|
2717 Michaelangelo Dr Ste 200, Edinburg, TX 78539-1412 | |
| (956) 362-2250 | |
| (956) 362-2251 |
| Full Name | Dr Relindis Neh-awah Azenwi Fru |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 9 Years |
| Location | 2717 Michaelangelo Dr Ste 200, Edinburg, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841687415 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | LP04454 (Rhode Island) | Secondary |
| 207RH0003X | Internal Medicine - Hematology & Oncology | S8957 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Doctors Hospital At Renaissance | Edinburg, TX | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Renaissance Medical Foundation | 1153409867 | 86 |
News Archive
The newly established Boston College Center on Aging & Work has received a $3-million grant from the Alfred P. Sloan Foundation to study how the American workplace will evolve to accommodate its aging workforce.
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
The University of Chicago Medicine and Advocate Children's Hospital / Advocate Health Care have received a five-year, $1.8-million grant from the National Institutes of Health to find new ways to delay and prevent type 1 diabetes. The grant will establish the first Type 1 Diabetes TrialNet Clinical Center in Chicago.
Projected cost increases for all types of medical plans are anticipated to be down by between 0.2 and 0.6 percent through the first half of 2013, according to a survey by Buck Consultants, A Xerox Company.
A groundbreaking study conducted by University of Pittsburgh Alzheimer's disease researchers reported in the journal Brain (currently online) confirms that Pittsburgh Compound-B (PiB) binds to the telltale beta-amyloid deposits found in the brains of patients with Alzheimer's disease.
› Verified 7 days ago
| Entity Name | Renaissance Medical Foundation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467633867 PECOS PAC ID: 1153409867 Enrollment ID: O20080422000326 |
News Archive
The newly established Boston College Center on Aging & Work has received a $3-million grant from the Alfred P. Sloan Foundation to study how the American workplace will evolve to accommodate its aging workforce.
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
The University of Chicago Medicine and Advocate Children's Hospital / Advocate Health Care have received a five-year, $1.8-million grant from the National Institutes of Health to find new ways to delay and prevent type 1 diabetes. The grant will establish the first Type 1 Diabetes TrialNet Clinical Center in Chicago.
Projected cost increases for all types of medical plans are anticipated to be down by between 0.2 and 0.6 percent through the first half of 2013, according to a survey by Buck Consultants, A Xerox Company.
A groundbreaking study conducted by University of Pittsburgh Alzheimer's disease researchers reported in the journal Brain (currently online) confirms that Pittsburgh Compound-B (PiB) binds to the telltale beta-amyloid deposits found in the brains of patients with Alzheimer's disease.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Relindis Neh-awah Azenwi Fru, MD Po Box 749, Pharr, TX 78577-1614 Ph: (956) 362-2250 | Dr Relindis Neh-awah Azenwi Fru, MD 2717 Michaelangelo Dr Ste 200, Edinburg, TX 78539-1412 Ph: (956) 362-2250 |
News Archive
The newly established Boston College Center on Aging & Work has received a $3-million grant from the Alfred P. Sloan Foundation to study how the American workplace will evolve to accommodate its aging workforce.
CureVac, a clinical stage biopharmaceutical company that has pioneered the development of a new class of therapies and vaccines based on messenger RNA (mRNA), today announced that it has entered into a collaboration and licensing agreement with Janssen Pharmaceuticals, Inc. Under the agreement CureVac will collaborate with Crucell Holland B.V. (a member of the Janssen Pharmaceutical Companies) on the development of an influenza vaccine based on CureVac's RNActive® technology.
The University of Chicago Medicine and Advocate Children's Hospital / Advocate Health Care have received a five-year, $1.8-million grant from the National Institutes of Health to find new ways to delay and prevent type 1 diabetes. The grant will establish the first Type 1 Diabetes TrialNet Clinical Center in Chicago.
Projected cost increases for all types of medical plans are anticipated to be down by between 0.2 and 0.6 percent through the first half of 2013, according to a survey by Buck Consultants, A Xerox Company.
A groundbreaking study conducted by University of Pittsburgh Alzheimer's disease researchers reported in the journal Brain (currently online) confirms that Pittsburgh Compound-B (PiB) binds to the telltale beta-amyloid deposits found in the brains of patients with Alzheimer's disease.
› Verified 7 days ago
Daniela Hernandez, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5423 S Mccoll Rd, Edinburg, TX 78539 Phone: 956-362-3575 Fax: 956-362-3584 | |
Dr. Carlos Javier Cardenas, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5520 Leonardo Da Vinci, Ste 100, Edinburg, TX 78539 Phone: 956-362-3636 Fax: 956-362-2699 | |
Chi Lun Pui, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2821 Michael Angelo, Ste. 400, Edinburg, TX 78539 Phone: 956-362-3553 | |
Dr. Brandon Robert Cantazaro, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5423 S Mccoll Rd, Edinburg, TX 78539 Phone: 956-362-3575 Fax: 956-362-3584 | |
Dr. Roque Masaharu Mifuji Lira, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5501 S Mccoll Rd, Edinburg, TX 78539 Phone: 956-362-3553 Fax: 956-362-3584 | |
Asma Salih Mohammed Tarjmani, Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 5501 S Mccoll Rd, Edinburg, TX 78539 Phone: 956-369-5100 | |
James Walter Castillo Ii, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5501 S Mccoll Rd, Edinburg, TX 78539 Phone: 956-362-8677 Fax: 956-362-7253 |